Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin

Giustino Parruti, Ennio Polilli, Federica Sozio, Valeria Cento, Alessandro Pieri, Francesco Di Masi, Fabio Mercurio, Monica Tontodonati, Elena Mazzotta, Francesca Ceccherini-Silberstein, Lamberto Manzoli, Carlo Federico Perno

Research output: Contribution to journalArticle

Abstract

The combination of pegylated interferons (PEG-IFNs) and ribavirin represents the standard of care for the treatment of chronic HCV-infected patients, yet with a success rate around 50% in genotypes 1 and 4, high costs and side effects. Therefore, early prediction of sustained virological response (SVR) is a relevant issue for HCV-patients. We evaluated the association between SVR and decline of HCV-RNA at 48. h in a prospective cohort of 145 HCV-patients treated with PEG-IFNs and ribavirin (males=69.1%; genotypes 1/4=51.0%; HIV-1 coinfected=6.7%). SVR was obtained in 65.5% of patients, while 16.6% experienced relapse and 17.9% no response. The first-phase of HCV-RNA decline clearly differentiated patients with SVR from relapsers and non-responders, independently of genotype (P0.5. log indicated a 6.8 odds ratio (95% C.I.: 2.0-23.2) for SVR after controlling for genotype, baseline viremia, adherence to therapy and HIV coinfection. Decays beyond the 0.5. log threshold were also strongly associated with and highly predictive of early virological response (95.0% positive predictive value, P

Original languageEnglish
Pages (from-to)124-127
Number of pages4
JournalAntiviral Research
Volume88
Issue number1
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Early SVR prediction
  • EVR prediction
  • HCV
  • HCV-RNA decay
  • PEG-IFN and ribavirin
  • Treatment

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Fingerprint Dive into the research topics of 'Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin'. Together they form a unique fingerprint.

  • Cite this

    Parruti, G., Polilli, E., Sozio, F., Cento, V., Pieri, A., Di Masi, F., Mercurio, F., Tontodonati, M., Mazzotta, E., Ceccherini-Silberstein, F., Manzoli, L., & Perno, C. F. (2010). Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research, 88(1), 124-127. https://doi.org/10.1016/j.antiviral.2010.08.003